Compare APA & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APA | MDGL |
|---|---|---|
| Founded | 1954 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 11.1B |
| IPO Year | 2021 | 2005 |
| Metric | APA | MDGL |
|---|---|---|
| Price | $32.99 | $503.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 23 | 12 |
| Target Price | $31.96 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 4.7M | 245.0K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.48% | N/A |
| EPS Growth | ★ 75.77 | 41.32 |
| EPS | ★ 1.26 | N/A |
| Revenue | N/A | ★ $180,133,000.00 |
| Revenue This Year | $3.86 | $58.39 |
| Revenue Next Year | N/A | $48.55 |
| P/E Ratio | $26.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.87 | $279.33 |
| 52 Week High | $45.66 | $615.00 |
| Indicator | APA | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 33.86 | 52.28 |
| Support Level | $22.73 | $498.59 |
| Resistance Level | $38.75 | $502.97 |
| Average True Range (ATR) | 1.17 | 19.92 |
| MACD | -0.46 | 2.65 |
| Stochastic Oscillator | 6.19 | 86.62 |
APA Corp is an independent exploration and production company. It develops and produces crude oil, natural gas, and natural gas liquids. The company's business has oil and gas operations in four segments: Egypt, the North Sea, Suriname, and the U.S. The company generates the majority of its revenue from the U.S. reporting segment. The company also has exploration interests in Uruguay, Alaska, and other international locations.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.